The right choice of testing partner?

It’s been a month since the European Medicines Agency human medicines committee recommended the suspension of marketing authorisations for generic medicines that had been tested by a large CRO in India, and it’s still making headlines today.

It was announced that medicines currently being evaluated for authorisation on the basis of data from that site will not be granted authorisation in the EU and that’s certainly caused ripples throughout the industry.

The irregularities that inspectors found in how bioequivalence studies were carried out not only caused general concern, but also major issues for those relying on the test results themselves. They must now provide alternative data demonstrating bioequivalence before licensing will be granted, which is not something easily achieved mid-project and at short notice.

Luckily, EU-based QUINTA-ANALYTICA can step in to help companies who now have this conundrum to solve.

With a highly experienced team and world-class approach they offer a complete solution for pharma companies, and their second newly opened, ultra-modern lab for pharmaceutical analyses in Brno provides ample capacity for projects of any size.

If your drug has been suspended, get in touch to see how we can help.

Additional News

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona